James R. Kasinger, the General Counsel and Secretary of CRISPR Therapeutics AG, has reported a series of stock transactions involving the company’s common shares. This update is significant as it reflects the ongoing management of executive compensation and stock ownership within the biotechnology sector.
Background
CRISPR Therapeutics AG, identified by CIK 0001674416, operates in the biological products industry, specifically focusing on innovative therapies. The company is incorporated in Zug, Switzerland, and trades under the symbol CRSP. Recent filings indicate continued activity in stock transactions, with the latest being reported on October 8, 2026.
What the Filing Says
According to the recent filing, Kasinger executed multiple transactions on October 6, 2026. He acquired 1,990 shares at a price of $13.62 each and subsequently disposed of 1,990 shares at a weighted average price of $60.0408. Following these transactions, he holds a total of 94,784 shares in the company.
Impact
These transactions may impact shareholders and potential investors as they reflect the confidence of company executives in the stock's future performance. Additionally, the biotechnology sector is closely monitoring such activities, which can influence market perceptions and investor sentiment.
What's Next
The filing does not say what happens next.
Additional Details from the Filing
In the filing, Kasinger also reported a stock option transaction on the same date, October 6, 2026. He exercised a stock option to acquire 1,990 shares at an exercise price of $13.62, which was granted on May 31, 2017. This option is part of a larger grant of 123,000 shares, with 25% vesting on May 31, 2018, and the remaining shares vesting monthly over the following three years.
After exercising this option, Kasinger’s total shares held increased to 81,242 shares. The filing notes that the stock option has an expiration date of May 31, 2027.
Trading Plan
Notably, the sales reported in this Form 4 were executed under a Rule 10b5-1 trading plan that Kasinger adopted on May 6, 2026. This type of plan allows executives to set up a predetermined schedule for selling shares, which can help avoid accusations of insider trading.
Conclusion
The filing provides insight into Kasinger’s ongoing management of his stock holdings and reflects the structured approach taken by executives in managing their equity compensation through trading plans.